On the heels of the US FDA accepting its non-small-cell lung cancer drug application, Adventrx Pharmaceuticals plans to raise $22.5 million through the sale of 8.2 million units at $2.75 per unit in a registered direct offering to RA Capital Management.
Each unit consists of one share of common stock, a Series A warrant and a Series B warrant.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?